Patient-reported outcomes from the randomized phase III CROWN study of first-line Lorlatinib versus in ALK+ NSCLC ...Middle East

Patient-reported outcomes from the phase III CROWN study showed that time to treatment deterioration (TTD) in pain in chest, dyspnea, and cough was comparable between those who received lorlatinib and patients who took crizotinib. The research was presented today at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer Singapore.

Read More Details
Finally We wish PressBee provided you with enough information of ( Patient-reported outcomes from the randomized phase III CROWN study of first-line Lorlatinib versus in ALK+ NSCLC )

Also on site :

• '90s Bombshell, 53, Makes Bold Statement About 'Natural Aging'
• Julia Fox's Net Worth in 2025 Proves She's an It Girl
• Israel strikes Syria again, claims to have killed alleged Hamas member